Denali Therapeutics Inc. (NASDAQ:DNLI) Position Trimmed by Wellington Management Group LLP

Wellington Management Group LLP trimmed its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 0.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,274,717 shares of the company’s stock after selling 14,243 shares during the quarter. Wellington Management Group LLP owned 5.23% of Denali Therapeutics worth $156,115,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CWM LLC boosted its stake in shares of Denali Therapeutics by 216.7% during the 4th quarter. CWM LLC now owns 2,011 shares of the company’s stock valued at $43,000 after buying an additional 1,376 shares during the period. Fisher Asset Management LLC purchased a new position in Denali Therapeutics in the fourth quarter valued at about $59,000. Assetmark Inc. increased its position in Denali Therapeutics by 65.3% in the 4th quarter. Assetmark Inc. now owns 3,550 shares of the company’s stock worth $76,000 after purchasing an additional 1,402 shares during the last quarter. Brandywine Managers LLC purchased a new stake in shares of Denali Therapeutics during the 4th quarter worth about $206,000. Finally, Quest Partners LLC acquired a new stake in shares of Denali Therapeutics during the 4th quarter valued at about $214,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. The Goldman Sachs Group cut their price objective on shares of Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th. HC Wainwright restated a “buy” rating and set a $95.00 price target on shares of Denali Therapeutics in a report on Wednesday, May 8th. Stifel Nicolaus decreased their price objective on shares of Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating for the company in a report on Wednesday, May 8th. UBS Group cut their target price on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, April 9th. Finally, Wedbush decreased their price target on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, May 8th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Denali Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $40.22.

Insiders Place Their Bets

In other news, Director Steve E. Krognes sold 92,500 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $20.50, for a total value of $1,896,250.00. Following the sale, the director now directly owns 47,341 shares in the company, valued at approximately $970,490.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Jennifer E. Cook sold 1,458 shares of Denali Therapeutics stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $21.73, for a total value of $31,682.34. Following the completion of the transaction, the director now directly owns 20,038 shares of the company’s stock, valued at $435,425.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steve E. Krognes sold 92,500 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $20.50, for a total transaction of $1,896,250.00. Following the sale, the director now directly owns 47,341 shares in the company, valued at approximately $970,490.50. The disclosure for this sale can be found here. Insiders sold a total of 95,624 shares of company stock worth $1,958,403 over the last quarter. Company insiders own 7.90% of the company’s stock.

Denali Therapeutics Trading Up 0.7 %

Shares of NASDAQ DNLI opened at $20.62 on Thursday. Denali Therapeutics Inc. has a one year low of $14.56 and a one year high of $33.11. The business has a fifty day simple moving average of $18.75 and a 200 day simple moving average of $19.12. The firm has a market capitalization of $2.94 billion, a price-to-earnings ratio of -21.48 and a beta of 1.37.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 11.46%. During the same period in the previous year, the business posted ($0.80) earnings per share. On average, research analysts anticipate that Denali Therapeutics Inc. will post -2.78 earnings per share for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.